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TRANSLATIONAL RELEVANCE 
Mutations in epidermal growth factor receptor (EGFR) drive 10-15% of non-small 
cell lung cancer. Although reversible EGFR tyrosine kinase inhibitors (TKIs) are 
superior to chemotherapy, tumors invariably develop drug resistance. Osimertinib, an 
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irreversible TKI, targets T790M-EGFR, the most common mode of resistance, but 
several compensatory mechanisms confer resistance to osimertinib. Currently, 
clinicians have no targeted treatment to offer their patients once they develop 
resistance to osimertinib. Herein we used an animal tumor model that initially 
responds to osimertinib but eventually relapses. The results show that a combination 
of intraperitoneal cetuximab and trastuzumab, along with low-dose oral osimertinib, 
can persistently prevent tumor relapses following either continuous or intermittent 
schedules. The observed long-term reversal of osimertinib resistance is attributable to 
simultaneous blockade of several compensatory mechanisms previously reported in 
patients. Hence, the ability to nullify resistance to osimertinib in a model system using 
commercially available drugs may inform clinical trial development. 
 
ABSTRACT 
Purpose: Because of emergence of resistance to osimertinib, a third-
generation EGFR tyrosine kinase inhibitor (TKI), no targeted treatments are available 
for patients with lung cancer who lose sensitivity due to new mutations or bypass 
mechanisms. We examined in animals and in vitro an alternative therapeutic approach 
making use of antibodies.   
Experimental Design: An osimertinib-sensitive animal model of lung cancer, 
which rapidly develops drug resistance, has been employed. To overcome 
compensatory hyper-activation of ERK, which we previously reported, an anti-EGFR 
antibody (cetuximab) was combined with other antibodies, as well as with a sub-
therapeutic dose of osimertinib, and cancer cell apoptosis was assayed.  
Results: Our animal studies identified a combination of three clinically 
approved drugs, cetuximab, trastuzumab (an anti-HER2 mAb) and osimertinib (low 
dose), as an effective and long-lasting treatment, able to prevent onset of resistance to 
osimertinib. A continuous schedule of concurrent treatment was sufficient for 
effective tumor inhibition and for prevention of relapses. Studies employing cultured 
cells and analyses of tumor extracts indicated that the combination of two mAbs and a 
sub-therapeutic TKI dose sorted EGFR and HER2 for degradation, cooperatively 
enhanced apoptosis, inhibited activation of ERK, and reduced abundance of several 
bypass proteins, namely MET, AXL and HER3.  
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Conclusions: Our in vitro assays and animal studies identified an effective 
combination of clinically approved drugs, which might overcome resistance to 
irreversible TKIs in clinical settings. The results we present attribute the long-lasting 
effect of the drug combination to simultaneous blockade of several well-characterized 
mechanisms of drug resistance. 
 
INTRODUCTION 
Defective vesicular trafficking and intracellular degradation of surface receptors, such 
as receptor tyrosine kinases (RTKs) or integrins, is emerging as a common feature of 
malignant cells (1). Accordingly, pharmacological interception of the propensity of 
tumor cells to derail their signaling or adhesion receptors may identify novel targets 
for cancer therapy. Herein we address the therapeutic potential of the ability of anti-
EGFR monoclonal antibodies (mAbs) to sort mutant EGFRs for intracellular 
degradation. Somatic mutations in the EGFR gene characterize approximately 15% of 
all non-small cell lung cancers (NSCLC) from Caucasian patients. While treatment 
with reversible EGFR-specific tyrosine kinase inhibitors (TKIs) is associated with 
response rates that are superior to treatment with chemotherapy, almost all patients 
acquire resistance within 10-14 months. The most common mechanism (>50%) of 
acquired resistance involves a second site mutation, T790M (2-5). Unlike patients 
who develop non-T790M resistance, for whom no targeted treatment options exist, 
second- and third-generation irreversible TKIs may be offered to T790M carriers (6). 
The most recently approved irreversible TKI is osimertinib, which selectively inhibits 
T790M-EGFR (7). Osimertinib demonstrated >50% response rate among T790M 
mutant tumors (8), greater efficacy than chemotherapy (9), as well as durable 
responses (10). Unfortunately, patients treated with osimertinib acquire resistance due 
to aberrant expression of NRAS and KRAS (11), activation of HER2 and MET (12), 
or emergence of a third site EGFR mutation, C797S (11, 13).  
Experimental strategies able to overcome resistance to osimertinib include an 
allosteric EGFR inhibitor (14) and an ALK inhibitor that cross-inhibits EGFR (15). 
Clinically approved anti-EGFR mAbs like cetuximab may offer an alternative to 
TKIs. Four clinical trials that investigated the addition of cetuximab to chemotherapy, 
observed small but consistent improvements in outcome in unselected patients with 
NSCLC (16). Similarly, a phase Ib study which combined an irreversible inhibitor, 
afatinib, and cetuximab found an overall objective response rate of 29% (17). 
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However, the rate was comparable in T790M-positive and T790M-negative tumors.  
We previously examined the ability of anti-EGFR mAbs to overcome resistance to 
TKIs and uncovered compensatory loops that up-regulated both HER2 and HER3, as 
well as hyper-stimulated ERK, in response to an anti-EGFR mAb (18). Preventing 
this by means of a triple combination of mAbs to EGFR, HER2 and HER3 
(hereinafter, 3XmAbs) arrested cell growth, sorted the three receptors for degradation, 
and robustly inhibited tumor growth in animal models. More recently, we 
demonstrated that 3XmAbs not only nullified osimertinib resistance in animal models, 
but it also synergized with sub-therapeutic doses of this TKI (19). 
Notably, T790M tumor-bearing mice were practically cured following a short 
(3 weeks) treatment with 3XmAbs plus osimertinib (19). Hence, we assumed that 
continuous or intermittent treatments with just two mAbs might retain efficacy. In line 
with this prediction the animal studies we present herein reveal that blocking 
EGFR+HER2 is as effective as blocking EGFR+HER3, but blocking HER2+HER3 is 
much less effective. Because no anti-HER3 drug has so far been approved, in the 
present study we supplemented osimertinib with cetuximab (anti-EGFR) and 
trastuzumab (anti-HER2). We report that no relapses occurred in animals 
continuously, or intermittently, treated with a combination of osimertinib and the two 
antibodies (2XmAbs). Furthermore, while all animals treated with osimertinib 
displayed relapses after a phase of tumor regression, treatment of the re-growing 
tumors with 2XmAbs+osimertinib resulted in rapid and persistent tumor inhibition. 
According to our studies, the underlying mechanism involves forced degradation of 
EGFR and HER2, inhibition of several bypass routes, along with enhanced cancer cell 
apoptosis.  
 
MATERIALS AND METHODS 
Materials  
Cetuximab, trastuzumab and osimertinib were obtained from Merck, Roche and 
Selleckchem, respectively, and a mAb to HER3 was generated in our lab (20). Unless 
indicated, antibodies were purchased from Cell Signaling Technology. PC9ER cells 
were cultured as described (Mancini et al., 2015). All cell lines were obtained from 
the American Tissue Type Culture Collection less than 3 years before starting the 
experiments. Periodic tests for Mycoplasms were performed using a commercially 
available kit. 
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Cell viability assays 
Viability of PC9ER cells was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT). Briefly, cells (6X10
4
) were seeded in triplicates 
in 96-well plates and treated with the indicated drugs for 48 hours. Subsequently, 
MTT was added and following 3 hours at 37°C, we dissolved in DMSO the water-
insoluble formazan crystals, which form in metabolically active cells. Optical density 
was measured at 570 nm. 
 
Cell cycle analysis and apoptosis assays 
Following 48 hours of treatment, PC9ER cells were incubated for 60 minutes with 
bromodeoxyuridine (BrdU; 10 μM) and then washed, harvested and fixed in ethanol 
(at 4
°
C). Thereafter, cells were incubated in a denaturation solution (2N HCl, 0.5% 
Triton-X100; 30 min), followed by a neutralization solution (0.1 M sodium borate, pH 
8.5; 30 min). BrdU that incorporated into newly synthetized DNA was then assayed 
using an APC-conjugated anti-BrdU antibody. Total DNA content was determined by 
using a propidium iodide (PI) solution supplemented with RNase A. Cell cycle 
distribution was detected by flow cytometry. Apoptosis assays were performed using 
the FITC Annexin V Apoptosis Detection Kit with 7-AAD (from BioLegend) and 
analyzed by flow cytometry. Both assays were performed on a BD FACSAria Fusion 
instrument controlled by BD FACS Diva software v8.0.1 (BD Biosciences). Further 
analysis was performed using the FlowJo software v10.2 (Tree Star). 
 
Immunofluorescence analyses 
Surface expression levels of specific RTKs were detected in vitro by means of 
immunofluorescence. The following anti-receptor antibodies were used: anti-EGFR 
(Cell Signaling, #4267S), anti-HER2 (Cell Signaling, #4290S) and anti-HER3 (Cell 
Signaling #12708S). Cells were grown for 24 hours on sterile coverslips and treated 
as indicated. Following 24 hours of treatment, cells were washed in PBS containing 
0.01% of Tween 20 (w/v). Thereafter, they were fixed in 4% formaldehyde in PBS 
(overnight at 4

C). After washing the cells on the next day, they were blocked with 
2% of fetal bovine serum, for 30 min. Next, cells were incubated overnight with anti-
receptor antibodies (1:50 dilution) at 4

C. Thereafter, cells were washed thrice, 
followed by the FITC-conjugated secondary antibody (for 45 min in dark), 
Research. 
on February 13, 2019. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 2, 2018; DOI: 10.1158/1078-0432.CCR-18-0450 
D. Romaniello et al., 2018  
 6 
counterstained with DAPI and mounted on slides for image capturing using a 
confocal microscope (40X magnification). Images were processed using the Zeiss 
ZEN2011 software.  
 
Flow cytometry analyses of surface receptors  
To evaluate surface receptor levels, cells were treated with trypsin and washed twice 
in saline containing albumin (1% w/v). Thereafter, cells were incubated for 30 min at 
4°C using antibodies to EGFR (clone AY13), HER2 (clone 24D2) and HER3 (clone 
1B4C3), which were conjugated to the following fluorophores: Alexa Fluor 488, 
allophycocyanin and phycoerythrin (BioLegend Inc). Fluorescence intensity was 
measured using BD FACSAria Fusion flow cytometer.  
 
Tumorigenic cell growth in mice 
All animal studies were pre-approved by the Weizmann Institute’s Review Board 
(IRB) and adhered to the NIH Guide for the Care and Use of Laboratory Animals. 
Mice were injected subcutaneously in the right flank with cancer cells (3-4X10
6
 per 
mouse). Antibodies were injected intraperitoneally at 200 μg (total) per mouse per 
injection, twice weekly. Daily administration of osimertinib used oral gavage. Tumor 
width (W) and length (L) were measured twice a week using a caliper and tumor 
volume (V) was calculated according to the following formula: V = 3.14×(W
2 
×L)/6. 
Body weight was evaluated once per week. Mice were euthanized when tumor size 
reached 1,500 mm
3
. Investigators were not blinded to the group allocation during the 
experiment and when assessing outcome.  
 
Statistical data analyses 
All data were analyzed using the Prism GraphPad software and statistical analyses 
were performed using one or two-way ANOVA with the Dunnett’s or Tukey’s test (*, 
p≤0.05; **, p≤0.01; ***. p≤0.001; ****, p≤0.0001). Flow cytometry analysis was 
performed on a BD FACSAria Fusion Instrument. Further analysis was performed 
using the FlowJo software v10.2 (Tree Star). Staining intensity was determined using 
ImageJ.  
 
RESULTS 
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Short treatments combining two or three anti-receptor antibodies with 
osimertinib variably inhibit an EGFR-driven NSCLC model 
No targeted therapy is currently available for treatment of NSCLC patients after they 
develop resistance to osimertinib (21). We previously reported that a 3-week long 
treatment of an erlotinib-resistant animal model (del746/50 and T790M) using a 
mixture of three antibodies and a sub-therapeutic dose of osimertinib inhibited tumor 
relapses, for at least 4 months after termination of all treatments (19). The unusually 
high and prolonged efficacy we observed in tumor-bearing mice prompted us to test 
simpler mixtures of mAbs, which might associate with reduced toxicity. Accordingly, 
we implanted erlotinib-resistant PC9ER cells carrying two EGFR mutations in the 
flanks of athymic mice, and randomized the animals to several arms once tumors 
reached approximately 450 mm
3
. To resolve small differences in efficacy, we limited 
all treatments to three weeks only: two antibody injections per week (intraperitoneal 
delivery) or a single daily treatment with osimertinib (oral delivery). As expected, a 3-
week long treatment with osimertinib (monotherapy), either high dose (H; 5 
mg/kg/day) or low dose (L; 1 mg/kg/day) resulted in complete or partial tumor 
shrinkage, respectively, but tumors re-appeared immediately after we stopped oral 
administrations (Figs. 1A and 1C). In contrast, treatment with 3XmAbs (cetuximab, 
trastuzumab and mAb33, a murine antibody specific to HER3) induced slower 
shrinkage of pre-established tumors, and subsequent relapses were delayed for 7-8 
weeks in this arm.  
As expected, the combination of low-dose osimertinib and 3XmAbs induced 
the strongest therapeutic effect: a 3-week treatment completely prevented any 
subsequent relapses (Figs. 1A and 1C). Notably, when tested alone or pairwise, none 
of the three antibodies caused tumor shrinkage comparable to the rapid and strong 
effect of high dose osimertinib. In contrast, although low-dose osimertinib (1 
mg/kg/day) caused only limited tumor shrinkage, when it was combined with 
antibodies we observed clear cooperative effects: three pairwise combinations of 
mAbs (topped with low dose osimertinib) were tested, and while none prevented 
relapses, two combinations: cetuximab + trastuzumab + osimertinib and cetuximab + 
mAb33 + osimertinib, were comparably effective and clearly superior to the effect of 
trastuzumab + mAb33 + osimertinib (Figs. 1A and 1B). Notably, a recent study 
combined cetuximab and the therapeutic dose of osimertinib (25 mg/kg/day), and 
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reported that nine out of ten PC9-T790M xenografts remained progression-free at 52 
weeks (Della Corte et al., 2018). Yet another study reported that one tenth of this dose 
(2.5 mg/kg) was sufficient for blocking both PC-9 (ex19del) and H1975 
(L858R/T790M) tumor xenograts (Cross et al., 2014). We conclude that antibody-
mediated targeting of the mutant form of EGFR, along with either co-receptor (i.e., 
HER2 or HER3) can achieve comparable delays of relapses, provided that a relatively 
low dose of osimertinib is simultaneously delivered.  
 
In vitro, osimertinib enhances the ability of a combination of cetuximab and 
trastuzumab to inhibit both viability and migration of NSCLC cells  
In comparison to 3XmAbs+osimertinib, the results presented in Figure 1 identified 
two simpler and relatively effective combinations: cetuximab+trastuzumab or 
cetuximab+mAb 33 (anti-HER3). Although several anti-HER3 antibodies have 
reached clinical trials, so far none has been approved for medical applications 
(reviewed in (22)). Because the profile of toxicity of trastuzumab is well 
characterized, but toxicity of anti-HER3 antibodies is only partly known, we focused 
all our subsequent animal studies on the combination of osimertinib (low dose) and 
the two clinically approved mAbs, namely cetuximab and trastuzumab (hereinafter, 
2XmAbs).   
In vitro assays that examined cell viability following 48 hours of drug 
treatment detected no marked effects of either antibody, or a combination of the two 
mAbs (Fig. 2A). In contrast, all treatments that used osimertinib, which we tested 
either at high (H; 500 nM) or low (L, 100 nM) concentrations, strongly inhibited cell 
viability. Notably, this in vitro assay detected no benefit of concurrent application of 
the TKI and the two antibodies. Hence, we employed two additional assays with the 
aim of understanding the cooperative in vivo effect of the drug combination. The first 
assay examined cell cycle distributions of PC9ER cultures following 48 hours of 
treatment with osimertinib, either alone or combined with antibodies (Fig. 2B). 
Unlike the viability assay, the cell cycle test detected a clear effect of 2XmAbs when 
applied alone: both the S-phase fraction and the G2/M fraction were reduced in 
response to the treatment, whereas the G0/G1 phase increased. As expected, 
osimertinib strongly reduced the S-phase fraction, but we observed a further 
diminution when the TKI was co-administered with 2XmAbs. Conceivably, 2XmAbs 
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arrests erlotinib-resistant PC9ER cells at the G0/G1 phase by activating a senescence-
like process (23-25), which we previously observed following treatment of NSCLC 
cells with 3XmAbs (19). Consistent with this interpretation, prolonged treatment of 
PC9ER cells with 2XmAbs strongly induced senescence-associated β-galactosidase 
(SA--Gal; Supplementary Fig. S1), a hallmark of cellular senescence (26). We noted 
that both cetuximab and trastuzumab induced partial effects on senescence, but 
prolonged treatments (>12 days) that included osimertinib promoted extensive cell 
death.  
Similar to the additive effects on cell growth, the other test we employed, a 
cell migration assay, detected a moderate cooperative action of the TKI and two 
mAbs (Fig. 2C). The ability of PC9ER cells, which were pre-plated on a porous filter, 
to migrate for 24 hours through the pores was strongly or weakly inhibited by 
osimertinib or 2XmAbs, respectively. A further, rather moderate but reproducible 
decrease in the ability of cells to migrate was observed when co-treated with a 
combination of osimertinib and the two antibodies (see data quantification in the 
lower part of Fig. 2C). In conclusion, the in vitro tests we employed detected 
cooperative inhibitory effects of the TKI+2XmAbs combination on both cell 
migration and G0/G1 cell cycle arrest. It is worth noting that the assays we used may 
be considered as relatively short snapshots, such that the observed, rather moderate 
cooperative effects, are likely amplified by the longer-term scale of the animal tests 
(weeks/months).  
 
Osimertinib and anti-receptor antibodies differently affect surface abundance of 
EGFR, HER2 and HER3 
Previous studies linked the anti-tumorigenic effects of anti-RTK antibodies to their 
ability to accelerate receptor endocytosis and degradation (27-29). Hence, we tested 
the ability of osimertinib, 2XmAbs and their combination to regulate the abundance 
of HER/ERBB family members. The first assay employed confocal microscopy, 
which was used to determine cell surface abundance of EGFR, HER2 and HER3 
following a 24-hour long treatment with the drugs (Fig. 3A). This assay revealed that 
exposure to osimertinib strongly up-regulated surface HER3, in line with a previous 
report, which inhibited AKT signaling and observed elevated expression of HER3 
(30). Unlike osimertinib, the mixture of two mAbs reduced staining with antibodies to 
EGFR and HER2, but HER3 displayed only moderate alterations. Congruent with 
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these observations, the combined treatment with 2XmAbs+osimertinib induced up-
regulation of HER3, along with downregulation of EGFR and HER2. To further 
characterize effects on HER3 and EGFR we used immunoblotting, which detects both 
surface and intracellular receptor levels (Figs. 3B). As expected, treatment with 
osimertinib alone blocked phosphorylation of EGFR, ERK and AKT, as well as 
increased HER3. In addition, 2XmAbs downregulated EGFR and HER2 and 
increased HER3 and pHER3. Notably, cells treated with the osimertinib+2XmAbs 
displayed very low levels of active EGFR, HER2, HER3, ERK and AKT. To quantify 
these effects and also focus on receptor molecules localized to the cell surface, we 
employed flow cytometry (Fig. 3C). As expected, the mixture of two antibodies, 
when tested alone, downregulated surface levels of both EGFR and HER2. In 
addition, we observed similarly strong (4-fold) increases in surface HER3 after 
treatment of cells with either osimertinib or the combination of osimertinib and 
2XmAbs. In conclusion, the three complementary assays we employed raised the 
possibility that the therapeutic effects observed when combining in animals 
osimertinib and 2XmAbs relate to the ability of this drug combination to 
downregulate signaling downstream to EGFR and the co-receptor, HER2. 
Nevertheless, the combination of mAbs and TKI was unable to abrogate (within 24 
hours) the ability of osimertinib to up-regulate surface HER3, a receptor involved in 
acquired resistance to TKIs (31).  
 
The combination of osimertinib and 2XmAbs increases apoptosis of erlotinib-
resistant NSCLC cells 
Previous studies reported that osimertinib induces apoptosis in a process involving 
up-regulation of PUMA (32) and BIM, along with downregulation of MCL1 (33). To 
examine the effect of 2XmAbs in combination with osimertinib, we probed PC9ER 
cells for annexin V and 7-amino-actinomycin D (7-AAD), which is excluded from 
early apoptotic cells, while late stage apoptotic cells stain positively due to passage of 
the dye into the nucleus. Due to long-term incubation times and cooperative effects of 
2XmAbs and sub-maximal osimertinib, our apoptosis tests made use of a relatively 
low concentration of osimertinib (40 nM). These tests detected strong apoptosis of 
PC9ER cells that were pre-treated for 72 hours with osimertinib, but 2XmAbs 
induced very weak apoptosis (Fig. 4A). Interestingly, however, treatment with a 
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combination of cetuximab, trastuzumab (each at 0.01 mg/ml) and osimertinib (40 
nM), followed by quantification of the fractions of early and late apoptotic cells 
showed that, in comparison to osimertinib alone, the antibodies increased cell death, 
primarily by enhancing early apoptosis. Next, we analyzed BIM, a pro-apoptotic 
protein, the abundance of which predicts TKI-induced suppression of lung tumors 
(34). Using an antibody specific to the three forms of BIM, we confirmed that protein 
levels were rather low in untreated cells, but a 24- to 48-hour long treatment with 
either 2XmAbs or osimertinib elevated the large (BIMEL), as well as the other forms 
of BIM (Figs. 4B and 4C). Interestingly, while osimertinib strongly induced cleavage 
of caspase 3, only weak cleavage was observed in 2XmAbs-treated cells. 
Nevertheless, co-treatments that used a combination of the TKI and the two mAbs 
more strongly activated caspase 3 and enhanced BIM’s abundance after 24 hours. In 
conclusion, the set of in vitro assays we performed confirmed the enhanced anti-
tumorigenic potential of co-treatments employing a TKI and a mixture of two mAbs. 
Notably, while osimertinib strongly inhibits cell cycle progression and induces death 
of EGFR-mutant expressing cells, treatment with 2XmAbs emerges as an inducer of 
cell cycle arrest, which can collaborate with osimertinib.  
 
Both continuous and intermittent treatments using a combination of two 
antibodies and a TKI robustly prevent resistance to osimertinib  
The in vitro validated positive mAb-TKI interactions raised the possibility that animal 
treatments longer than the three weeks period we applied (see Figure 1) might delay 
onset of resistance. To test this prediction, we compared the drug holiday scenario 
with either a continuous administration protocol or with an intermittent drug delivery. 
The continuous protocol was first applied to mono-therapy osimertinib, either low (1 
mg/kg) or high dose (5 mg/kg; Fig. 5A). For this, we implanted PC9ER cells in the 
flanks of 9 athymic mice and, once tumors became palpable, orally delivered 
osimertinib once daily. As expected, within the first 2-3 weeks of treatment all 
animals displayed rapid tumor shrinkage (note that each color represents one animal). 
However, following a variable length remission (50-110 days), eight of nine animals 
displayed relapses and their tumors were sampled for future transcriptomic/proteomic 
analyses.  
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 Using a similar tumor implantation protocol, which was followed by a 3-week 
long treatment with 2XmAbs plus osimertinib (1 mg/kg), we confirmed the initial 
pattern of rapid shrinkage of pre-established tumors (Fig. 5B). However, 
approximately 60 days after termination of all drug deliveries, we observed the 
beginning of a variable phase of relapse. Altogether, relapses took place in 6 out of 
the 16 animals used in this arm. Two variants of the protocol of Figure 5B were used 
side-by-side: (i) a ‘No Holiday’ group, which was continuously treated with low-dose 
osimertinib and 2XmAbs (Fig. 5C), and (ii) an ‘Intermittent’ group, which was 
similarly treated for 21 days, but this was followed by 4 cycles of a holiday (14 days) 
and treatment (7 days; Fig. 5D). Note that for ethical reasons, the regimen applied to 
the ‘No Holiday’ group was changed from a daily oral osimertinib administration to 
once every other day, but the concomitant 2XmAbs treatment remained unaltered.  
 The results we observed in the ‘No Holiday’ group were quite encouraging: no 
relapses were observed, provided that treatment was carried out continuously. 
Similarly, although small and transient relapses were initially observed in the 
‘Intermittent’ group, following 2-3 treatment-holiday cycles all tumors, with no 
exception, were completely eradicated. In conclusion, admixing two antibodies and a 
sub-therapeutic dose of the TKI completely and persistently inhibited resistance of 
T790M-expressing mouse models. However, the striking effects we observed required 
continuous or intermittent treatments using a combination of three drugs.  
 
In response to the combined ‘antibodies plus TKI’ treatment, tumors shut down 
multiple bypass pathways and strongly activate apoptosis 
Mechanisms of acquired resistance to EGFR-specific TKIs may be divided into 
EGFR-dependent (e.g., new mutations or EGFR amplification) and EGFR-
independent modes (35). The latter mode of resistance often involves activation of a 
surrogate RTK. For example, activation of MET and HER2 was found in patients who 
acquired resistance to osimertinib (36). Another RTK, AXL, is an oncogenic receptor 
implicated in both inhibition of apoptosis and resistance to drugs (37-39). Notably, 
the most prevalent mechanism of resistance, namely amplification of MET (40, 41), 
promotes formation of MET-HER3 complexes, which restore an AKT-mediated anti-
apoptosis pathway (42). Similarly, HER2 is amplified in 12% of tumors with acquired 
resistance (43). To examine RTK alterations and apoptosis, we treated pre-established 
PC9ER xenografts with either osimertinib, a mixture of two antibodies (2XmAbs), or 
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a combination of all three drugs. Tumor extracts were prepared seven days after 
treatment initiation, and they were subjected to immunoblotting using anti-RTK 
antibodies. As shown in Figure 5E, a seven-day long treatment with 2XmAbs, either 
alone or in combination with osimertinib, effectively downregulated not only EGFR 
and HER2, but also HER3, MET and AXL. By contrast, animal treatment with 
osimertinib alone exerted much weaker effects on RTK levels and, in similarity to the 
in vitro assays shown in Figure 3, strongly elevated HER3 expression, a potential 
mechanism of therapeutic resistance (44). Notably, however, this putative bypass loop 
was nullified when osimertinib was combined with 2XmAbs (Fig. 5E). To 
corroborate the observed effects on RTK abundance, we analyzed tumors from 
additional animals. Altogether, six tumor-bearing mice were analyzed. This is 
exemplified by Supplementary Figure S2, which quantitatively analyzed two 
additional mice and confirmed simultaneous downregulation of five RTKs (EGFR, 
HER2, HER3, MET and AXL) by 2XmAbs+osimertinib, already after 3 days of 
treatment.  
 Because all three treatments we examined in animals inhibited, in part, the 
active forms of both ERK and AKT, a survival-supporting kinase, we probed for two 
markers of apoptosis, caspase 3 and BIM. Tumor extracts were prepared 3, 7 and 14 
days following treatment initiation and probed with the respective antibodies. In line 
with the in vitro assays of apoptosis (see Fig. 4), we observed cooperative activation 
of caspase 3, along with a marked induction of all three forms of BIM, which is 
known to release cytochrome C from mitochondria and consequently activate caspase 
3 (Fig. 5F). In conclusion, biochemical analyses of NSCLC xenografts attributed the 
anti-tumor efficacy of the combination of antibodies and osimertinib to an ability to 
degrade EGFR, as well as to block its intrinsic catalytic activity, and to a concomitant 
antibody-induced shutdown of several mechanisms of resistance involving surrogate 
RTKs, namely HER2, HER3, MET and AXL.   
 
Combining osimertinib and two (or three) mAbs eradicates tumors after they 
acquired resistance to osimertinib 
No upfront polytherapy is currently used to treat patients with the T790M mutation 
(21). Instead, once patients are diagnosed with a primary site EGFR mutation they 
receive treatment with a first-generation drug (e.g., elrotinib), and those who develop 
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resistance due to the T790M mutation receive osimertinib till resistance emerges. To 
simulate this scenario and test if a combination of osimertinib and mAbs can inhibit 
tumors after they acquired resistance to osimertinib, we adopted a second line 
protocol: erlotinib-resistant cells were implanted under the skin of mice and once 
tumors reached a volume of 400-600 mm
3
, mice were orally treated with osimertinib 
(1 mg/kg), once per day. Invariably, all tumors regressed and after 3-4 weeks they 
started to relapse. Once they re-gained 400-600 mm
3
, mice were randomized and 
received the following treatments: (i) 3XmAbs plus low-dose osimertinib (Fig. 6A), 
or (ii) 2XmAbs plus low-dose osimertinib (Fig. 6B). Remarkably, all animals treated 
with the combination of osimertinib and either two or three mAbs showed complete 
tumor elimination 2-6 weeks later, and no relapses were detected.  
Next, we asked if osimertinib was necessary after commencement of antibody 
treatment. To this end, we used the protocol of Figure 6, but once regrowth was in full 
swing we switched to treatments containing mAbs only, either three antibodies 
(3XmAbs; Supplementary Figure S3A) or two antibodies (2XmAbs; Supplementary 
Figure S3B). Unlike the uniform eradication of tumors observed when we combined 
osimertinib and antibodies, the omission of osimertinib resulted in variable responses, 
ranging from rapid tumor eradication to tumor progression. Taken together, this and 
other observations we made underscore the power of concurrent, rather than 
sequential, treatments making use of antibodies and a TKI. Furthermore, our results 
attribute the cooperative TKI-mAb effects to shutdown of evasion mechanisms 
previously reported in osimertinib-treated patients. Thus, the animal studies and the 
results we obtained in vitro identify 2XmAbs plus osimertinib as a highly effective 
and commercially available combination, which might warrant trials in clinical 
settings.  
 
DISCUSSION 
Our motivation to examine the antibody alternative to lung cancer treatment has 
stemmed from the recurring relapses observed in almost all patients treated with first-, 
second- and third-generation TKIs. The cellular system we applied, namely PC9ER 
cells, reliably recapitulates the recurring cycles of drug sensitivity followed by tumor 
relapses. For example, the data shown in Figure 5A demonstrate rapid and general 
tumor relapses, which exhibited animal-specific variation in terms of onset and rate of 
re-growth. We previously reported that emergence of the C797S mutation and 
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overexpression of EGFR characterize some relapsing tumors in the PC9ER model 
(19). To overcome insurgence of resistance, our immunological strategy underwent a 
three-step evolutionary process, which led to the herein proposed combination of 
2XmAbs (i.e., cetuximab and trastuzumab) and a sub-therapeutic dose of osimertinib. 
In the first step we examined a single, home-made anti-EGFR antibody (18). 
Although the antibody robustly downregulated EGFR, we observed marked activation 
of downstream signalling due to two bypass feedback loops, which elevated HER2 
and HER3. Concurrent inhibition of EGFR, HER2 and HER3 prevented over-
activation of ERK and effectively inhibited tumor growth. In the second step we 
contrasted the mechanisms underlying the anti-tumorigenic effects of osimertinib and 
3XmAbs, a combination of cetuximab, trastuzumab and a home-made anti-HER3 
antibody (19). Because osimertinib induced apoptosis of PC9ER cells but 3XmAbs 
arrested cell growth, while activating a senescence-like process, we combined the two 
treatments. Remarkably, tumors were persistently eradicated after just 3 weeks of 
treatment. To reduce potential skin and gastrointestinal toxicities, due to the inclusion 
of an anti-HER3 antibody, we tested in the present study a simpler combination, 
which included three clinically approved drugs, namely cetuximab, trastuzumab and 
osimertinib.  
 The major finding reported herein is the surprisingly strong and durable 
effects exerted in vivo by a combination of two antibodies and a sub-optimal dose of 
osimertinib. Only a fraction of this synergistic effect was captured by our in vitro 
assays of cell cycle progression and migration, but this might be due to the short-term 
nature of the in vitro treatments. Notably, it has previously been reported that a 
combination of a TKI (i.e., afatinib) and cetuximab might overcome T790M-mediated 
resistance in clinical settings (17). In our animal model a single mAb was insufficient; 
the combined effect of osimertinib and cetuximab was greatly enhanced by either 
trastuzumab or by an antibody to HER3 (Fig. 1). By contrast, a triplet containing 
trastuzumab, our home-made anti-HER3 antibody and osimertinib, was inferior in 
animals, in line with the driver function of mutant EGFRs.  
 In view of the added value of simultaneously blocking both the mutant form of 
EGFR and the wild type form of HER2, it is worthwhile reviewing the role played by 
HER2 in NSCLC (45). HER2 aberrations, including amplification and mutations, 
have been classified as oncogenic drivers involved in 2-6% of lung adenocarcinomas. 
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HER2 amplification serves also as an important mechanism of acquired resistance to 
EGFR kinase inhibitors, including osimertinib (46). FISH analysis revealed that 
HER2 was amplified in 12% of tumors with acquired resistance to EGFR inhibitors, 
versus only 1% of untreated lung adenocarcinomas (47). Moreover, HER2 
amplification and presence of EGFR(T790M) were mutually exclusive. In addition, 
HER2 amplification, as well as amplification of MET, have been found in patients 
who developed resistance to osimertinib (12). Altogether, these lines of evidence and 
the herein reported cooperative effects of cetuximab and trastuzumab, portray HER2 
as a major partner of mutant forms of EGFR in lung tumors. 
Understanding how exactly do cetuximab and trastuzumab collaborate with 
osimertinib remains a matter for further investigation. Evidently, the two antibodies 
not only block the EGFR pathway, but also inhibit multiple surrogate routes, namely 
HER2, HER3, MET and AXL, which are often activated in drug-resistant tumors 
(48).  In line with concurrent inactivation of several, partly redundant, survival 
pathways, we observed growth arrest both in vitro and in animals, along with 
sensitization of cells to the apoptosis-inducing action of osimertinib. Our working 
hypothesis assumes that cetuximab sorts EGFR to degradation in lysosomes, while 
osimertinib inhibits kinase activity of the remaining T790M-EGFR molecules, and the 
combination with trastuzumab blocks frequent routes of drug resistance. Unlike the 
well-understood inhibition of EGFR by both a TKI and a mAb, mechanisms enabling 
inhibition of several bypass receptors remain unknown. For example, this might be 
achieved by a RAB-family member, such as RAB25, which regulates recycling of 
both RTKs and integrins (49). Alternatively, catalytic activation of ADAM-family 
surface proteases by the combination of mAbs and osimertinib may underlay 
shedding of the ectodomain of several RTKs, thereby explains the observed 
disappearance of RTKs like MET and AXL (Fig. 5E). 
In summary, our study reports for the first time a potential therapeutic 
intervention for TKI-resistant lung cancer, namely a combination of two mAbs and a 
sub-therapeutic dose of osimertinib. The proposed intervention is able to completely 
disarm mutant EGFRs and, at the same time, block several bypass routes. Hence, 
regardless of the underlying molecular mechanisms, the cocktail of three clinically 
approved drugs offers hope for patients who are currently developing resistance to 
osimertinib and remain with no targeted treatment options.  
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FIGURES AND LEGENDS TO FIGURES 
Fig. 1. Combining different anti-receptor antibodies with a kinase inhibitor 
variably inhibits an EGFR-driven lung cancer model. PC9ER cells (4X10
6
 cells 
per animal) were subcutaneously implanted in CD1-nu/nu mice. When tumors 
became palpable, mice were randomized into groups of 7-9 animals that were later 
treated for 3 weeks (hatched area) with the indicated antibodies (total dose: 0.2 
mg/mouse/injection) once every 3 days, or with osimertinib, either high dose (H; 5 
mg/kg/day), or low dose (L; 1 mg/kg/day). In addition, we tested the indicated 
combinations of mAbs and the kinase inhibitor. Note that all treatments were stopped 
on Day 21. However, tumor growth was followed for approximately 100 additional 
days (A and B), and animal survival was followed for 180 days and presented as 
Kaplan-Meyers curves (C and D). Mice were euthanized when tumor size reached 
1,500 mm
3
. Data are means ± SEM from 7-9 mice of each group. Note that for 
technical reasons, we aborted the cetuximab + osimertininb (L) arm on day 61. 
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Fig. 2. Osimertinib treatment decreases cell viability and, when combined with 
2XmAbs, it decreases cell migration and cell cycle progression. (A) PC9ER cells 
were cultured for 48 hours and later incubated with the following agents: osimertinib, 
either low dose (L; 0.1 M) or high dose (H; 0.5 M), cetuximab (0.02 mg/ml), 
trastuzumab (0.02 mg/ml) or a combination of the two antibodies. Cell viability was 
determined using the MTT assay. Data are means ± S.D. values from three 
experiments. (B) PC9ER cells (100,000 per sample) were treated for 48 hours with 
saline, 2XmAbs (cetuximab plus trastuzumab; 0.02 mg/ml), osimertinib (0.1 M), or 
with the two treatments combined (2XmAbs and osimertinib). Following incubation 
with BrdU (60 min), cells were fixed and subjected to BrdU and propidium iodide 
(PI) detection. Shown are the means of cell cycle distributions observed in three 
experiments that used cytometry. (C) PC9ER cells (2X10
4
) were seeded in duplicates 
on filters of transwell chambers under the indicated treatments (see B for the doses). 
The upper panel shows representative images of cells that migrated to the lower side 
of the filters (scale bars, 500 m). The histogram shows quantification of migrated 
cells relative to control. *, p=0.0173; ns, not significant.  
 
Fig. 3. The combination of osimertinib and two mAbs reduces EGFR and HER2 
abundance. (A) PC9ER cells were seeded on cover slips and treated for 24 hours 
with saline (Control), 2XmAbs (cetuximab and trastuzumab; 20g/ml total), 
osimertinib (100 nM), or with the combination (2XmAbs plus osimertinib). Cells 
were later fixed in formaldehyde (4%) and incubated with specific primary 
antibodies, followed by a secondary, FITC-conjugated antibody. DAPI staining (blue) 
indicates locations of nuclei. Images were captured using a confocal microscope (40X 
magnification). Bar (white, vertical), 50 (B) PC9ER cells were treated for 24 
hours with vehicle (DMSO), increasing concentrations (25, 50, 100 nM) of 
osimertinib (Os.), 2xmAbs (cetuximab and trastuzumab, 20 μg/mL total), or the 
combination (2xmAbs plus Os.).  Cell extracts were blotted and probed for the 
indicated proteins. GAPDH and tubulin served as loading control. (C) PC9ER cells 
were treated for 24 hours with saline (CTRL), 2XmAbs (20 g/ml), osimertinib (100 
nM), or with the combination (2XmAbs plus osimertinib). Thereafter, cells were 
analyzed, using flow cytometry, for surface expression levels of EGFR, HER2 and 
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HER3. Normalized surface expression levels (means of two independent experiments) 
are shown. 
 
Fig. 4. The combination of osimertinib and 2XmAbs increases apoptosis of 
erlotinib-resistant NSCLC cells. (A) PC9ER cells were treated for 72 hours with the 
following agents: saline (PBS), 2XmAbs (cetuximab and trastuzumab, each at 0.01 
mg/ml), osimertinib (40 nM), or the combination of 2XmAbs and osimertinib. Shown 
are results of an apoptosis assay performed using an annexinV/7-AAD kit 
(BioLegend, Inc.). Quantification of the fractions of early and late apoptotic cells is 
shown in histograms. The experiment was repeated three times. Note the isoforms of 
BIM. (B) PC9ER cells were treated for 24 or 48 hours with saline, osimertinib (40 
nM), 2XmAbs (cetuximab and trastuzumab, each at 0.01 mg/ml), or with a 
combination of 2XmAbs and osimertinib. Shown is a representative immunoblot 
probed with antibodies to caspase 3 or to BIM. GAPDH levels were used to control 
gel loading. Control samples were treated with the solvent of osimertinib (DMSO) or 
with saline. (C) PC9ER cells were treated with osimertinib (as indicated) for 48 
hours, and extracts were blotted using the indicated antibodies.  
 
Fig. 5. Continuous treatments using a combination of two antibodies reverses 
resistance to osimertinib, downregulates several RTKs and cooperatively 
activates apoptosis. (A-D) PC9ER cells (2x10
6
) were subcutaneously engrafted in 
CD-1 nu/nu mice. Once tumors became palpable, mice were subdivided into several 
groups. Note that each colored line represents one animal. Mice of the 
OSIMERTINIB group (A) were treated daily, for 60 days, with oral osimertinib, 
either low dose (1 mg/kg; dotted lines) or high dose (5 mg/kg; solid lines). Thereafter, 
we switched to osimertinib treatment every other day (dotted underneath line). (B) 
Palpable tumors of the HOLIDAY group were treated twice a week with 2XmAbs 
(0.2 mg/mouse/injection) plus daily oral osimertinib administrations (1 mg/kg). All 
treatments were stopped on day 21 and tumor volumes were monitored in the next 4 
months. (C) Tumors of the NO HOLIDAY group were treated as in B twice a week 
with a combination of cetuximab and trastuzumab, combined with daily 
administrations of osimertinib (1 mg/kg). This regimen was changed on day 60 to 
osimertinib treatment once every other day, but mAb treatment remained unaltered 
(underneath dotted line). (D) The INTERMITTENT group was treated for 21 days, 
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twice a week, with 2XmAbs plus daily osimertinib (1 mg/kg). This was followed by 4 
cycles of a break (14 days) and treatment (7 days), as indicated by the underneath 
segmented line. (E-F) Tumor-bearing mice (see above) were randomized into groups 
of 3 animals. Osimertinib (1 mg/kg/dose) was daily administered using oral gavage, 
whereas the antibody combination (2XmAbs, cetuximab and trastuzumab; 0.2 
mg/mouse/injection) was administered intraperitoneally once every three days. Shown 
are immunoblots of tumor extracts isolated one week after treatment initiation (E) or 
3, 7 and 14 days after treatment onset (F). Note that the three forms of BIM are 
shown. 
  
Fig. 6. Combining a low dose of osimertinib with mixtures of either two or three 
monoclonal antibodies (2XmAbs or 3XmAbs) eradicates osimertinib-resistant 
tumors. PC9ER cells (2x10
6
) were subcutaneously injected in the flanks of CD-1 
nu/nu mice. Once tumors reached a volume of 300-600 mm
3
, mice were orally treated 
with osimertinib (1 mg/kg), once per day. Invariably, tumors regressed and thereafter 
relapsed. Once relapsing tumors reached their original volume, mice were randomized 
and injected intraperitoneally twice a week with either 3XmAbs (A) or with 2XmAbs 
(B), while still receiving daily oral treatments with osimertinib. Note that each panel 
displays results obtained using one animal. 
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